OncRef

Clinical Trial: NCT05043090

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 3

Lead Sponsor:AstraZeneca
Information Provided By:AstraZeneca
Last Update Posted:2026-10-21

Study Overview

Brief Summary

A clinical trial to compare the effectiveness of savolitinib plus durvalumab versus sunitinib in MET-driven (hepatocyte growth factor receptor), unresectable and locally advanced or metastatic PRCC (Papillary Renal Cell Carcinoma).

Official Title

A Phase III, Open Label, Randomised, 3-Arm, Multi-Centre Study of Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (SAMETA)

Conditions

Papillary Renal Cell Carcinoma

Intervention / Treatment

  • Drug: savolitinib
  • Drug: durvalumab
  • Drug: sunitinib

Other Study ID Numbers

  • D5086C00001
  • 2022-503105-38-00
  • 2021-000336-55

Start Date (Actual)

2021-10-28

Primary Completion Date (Actual)

2025-12-31

Study Completion Date (Estimated)

2027-02-01

Enrollment (Actual)

148

Study Type

Interventional

Phase

Phase 3